• Technology
  • Overview
  • Case Studies
  • Development Programs
  • Publications
• Applications
• Community
• News & Events
  • Press Releases
  • Events
• Corporate
  • Our Company
  • Leadership
    • Gregory J. Galvin
    • Tony Eisenhut
    • Peng Zhou
    • Richard Montagna
    • John Brenner
    • Christopher Smith
    • Lincoln Young
    • Gwendolyn Spizz
  • Contact Us
  • Careers
• 
Follow Rheonix®

PARTNERSHIPS

Rheonix® has established corporate, governmental, and educational partnerships worldwide.

The Company is currently the recipient of government funds for the development of systems that meet specific detection needs:

• National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) – Rheonix has been awarded a Partnership Grant to work with both the NIAID and Cornell University to develop a disposable point-of-care (POC) diagnostic device for the rapid detection of various sexually transmitted diseases in human specimens.  The $1.67 Million contract has been awarded to permit the integration of an electronic biosensor technology, exclusively licensed from Cornell, into its fully automated CARD® microfluidic platform to achieve true sample in–results out capabilities.  Once a raw clinical specimen is introduced, all assay functions will be performed automatically on the integrated CARD™, achieving easy-to-interpret electronic results.  Another major goal of this NIH initiative is to develop POC devices for use in nontraditional healthcare settings.
  
  
• United States Environmental Protection Agency (US EPA) - Rheonix is currently under contract to complete the development and testing of a fully-automated system for the detection of Cryptosporidium parvum in drinking water. With the goal to improve water testing within the US, Rheonix is in the final stages of completing the development process and having the resulting product verified by an independent testing laboratory. The CARD® product will be able to detect as few as one organism and distinguish viable from nonviable oocysts in a sophisticated molecular assay.
  
  
• National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) - Rheonix is currently the recipient of a grant to demonstrate that the CARD™ can be used to quickly and easily detect the presence of Mycobacterium tuberculosis in human clinical specimens. Successful completion of this project will not only provide a valuable tool for monitoring for the presence of the causative agent of TB, especially in developing nations, but will also provide an additional framework upon which other infectious disease agents can be quickly and easily detected.
  
  
• National Science Foundation (NSF) - Rheonix is currently the recipient of an NSF grant to develop a CARD® assay for the detection of various waterborne pathogens found in recreational waters.  The test under development will also provide diagnostically-important information about the viability of the pathogens.  This test will eliminate the existing, unacceptable delays in announcing beach closings, a result of the inadequate technology currently used by public health authorities to monitor beach-water safety.  Such delays of several days can have serious effects on the health of bathers.  Moreover, since the U.S. EPA is currently under a court order to reduce the time required to perform such tests to same-day results, the versatile capabilities of the Rheonix CARD® system, to automatically perform all assay functions without user intervention, will help to achieve this goal and dramatically improve public health.

A number of important collaborations with major universities have allowed Rheonix to gain third-party validation of the utility of the CARD® technology:

• New York University (New York, NY, USA).
• University of Pennsylvania (Philadelphia, PA, USA).
• Leiden University (Leiden, The Netherlands)
• Cornell University (Ithaca, NY, USA)

Rheonix is engaged in multiple corporate-funded partnerships addressing a variety of applications that can benefit from the CARD® technology:

• In vitro diagnostics, including immunoassay, molecular assays, and receptor-based assays.
• Environmental testing, including food and water testing.
• Bioburden testing during the manufacture of products in the biopharm, food and beverage, and personal care markets.
• Flow injection analysis
• Protein/Nucleic Acid purification

A joint-venture with Beijing Bohui Innovative Technology Co., Ltd. (Beijing, China) provides Rheonix with not only access to the expanding diagnostic markets in China, but also state-of-the-art medical device manufacturing facilities.

To discuss a partnership that brings our platform technology to your existing or future products or services, please contact us.

Companies and agencies already partnering with Rheonix to develop new assays or transform existing "bench top" assays may log in here with your unique user name and password to view project progress.